Edition:
United States

Curis Inc (CRIS.O)

CRIS.O on Consolidated Issue listed on NASDAQ Global Market

1.70USD
20 Sep 2017
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.70
Open
$1.71
Day's High
$1.73
Day's Low
$1.67
Volume
477,577
Avg. Vol
583,079
52-wk High
$3.72
52-wk Low
$1.47

Chart for

About

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of... (more)

Overall

Beta: 1.92
Market Cap(Mil.): $276.96
Shares Outstanding(Mil.): 163.88
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Curis announces pricing of public offering of common stock

* Curis Inc - pricing of an underwritten public offering of 20 million shares of its common stock​ Source text for Eikon: Further company coverage:

Sep 14 2017

BRIEF-Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

* Curis and Aurigene announce CA-170 program update following data presented at ESMO 2017

Sep 11 2017

BRIEF-Curis reports Q2 loss per share $0.10

* Q2 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Aug 03 2017

BRIEF-Curis Q1 loss per share $0.11

* Q1 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S

May 04 2017

Earnings vs. Estimates